Last reviewed · How we verify

Methotrexate,Calcium folinate

Tianjin Medical University Cancer Institute and Hospital · Phase 1 active Small molecule ✓ Verified May 2026 Quality 15/100

Methotrexate,Calcium folinate is a Small molecule drug developed by Tianjin Medical University Cancer Institute and Hospital. It is currently in Phase 1 development.

Methotrexate is a small molecule used in the treatment of various types of leukemia, including Acute Lymphoblastic Leukemia, as indicated by ClinicalTrials.gov. Calcium folinate, also known as calcium levofolinate, is a compound with an unknown mechanism of action, as stated by ChEMBL.

Likelihood of approval
9.6% vs 9.6% industry baseline
If approved by FDA: likely 2033–2036
Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 1 → approval rate +9.6pp
    Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2033–2036
EMA EU 2034–2037 +0.7 yr
MHRA GB 2034–2037 +0.7 yr
Health Canada CA 2034–2038 +0.9 yr
TGA AU 2034–2038 +1.2 yr
PMDA JP 2034–2038 +1.5 yr
NMPA CN 2035–2039 +2.3 yr
MFDS KR 2034–2038 +1.4 yr
CDSCO IN 2034–2039 +1.8 yr
ANVISA BR 2035–2039 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameMethotrexate,Calcium folinate
SponsorTianjin Medical University Cancer Institute and Hospital
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Methotrexate,Calcium folinate

What is Methotrexate,Calcium folinate?

Methotrexate,Calcium folinate is a Small molecule drug developed by Tianjin Medical University Cancer Institute and Hospital.

Who makes Methotrexate,Calcium folinate?

Methotrexate,Calcium folinate is developed by Tianjin Medical University Cancer Institute and Hospital (see full Tianjin Medical University Cancer Institute and Hospital pipeline at /company/tianjin-medical-university-cancer-institute-and-hospital).

What development phase is Methotrexate,Calcium folinate in?

Methotrexate,Calcium folinate is in Phase 1.

What are the side effects of Methotrexate,Calcium folinate?

Common side effects of Methotrexate,Calcium folinate include Infections and infestations - Other, specify, Neutrophil count decreased, Alanine aminotransferase increased, Febrile neutropenia, Hyperglycemia, Platelet count decreased.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing